Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease
PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered ...